NEW YORK — Apr 21, 2020 — Acuamark Diagnostics, Inc. (“AcuamarkDx”), a biotechnology company that focuses on developing innovative blood-based screening assays for reliable and cost-effective detection of early-stage cancer, today announced the appointment of William Gedale as its Executive Chairman. Mr. Gedale will replace Mr. Michael Gargano as Chairman of the Company.
“I have great expectations for Acuamark Diagnostics and its team. The Company has come a long way in de-risking its innovative and unique early-cancer detection approach,” Said Michael Gargano. “It has been an honor to serve as AcuamarkDx’s Chairman, and for this next phase, I am excited to entrust the Executive Chairman role into the capable and experienced hands of Mr. William Gedale. The future has great things in store for Acuamark Diagnostics and its team, and I can’t wait to see the company’s early detection products benefit cancer patients worldwide.”
William (“Bill”) J. Gedale originally joined AcuamarkDx’s Board of Directors in 2014. Previously, Bill was a Director at BioArray Solutions (Immucor), Unilab Corporation (Quest), Allied Clinical Laboratories (LabCorp), BioReliance (Life Technologies). He was also an Advisor to Exosome Diagnostics (BioTechne), and Advisor to Warburg Pincus, President/CEO of General American Investors and co-founder of NGN Capital, a trans-Atlantic life sciences VC fund. William Gedale holds an M.B.A. from New York University and a J.D. from Fordham Law School.
Mr. Gedale stated, “I first want to express my appreciation for Michael’s exemplary service as Chairman, and I look forward to working with our President & Chief Executive, Bernard Peperstraete, Michael, our other directors and other employees to achieve our goal of improved early-cancer testing for early detection.”
Dr. Peperstraete, CEO of AcuamarkDx adds, “Michael has been incredibly supportive of the company team over all of these years. He has been a haven of thoughtful insight and balanced judgment. I am looking forward to working with both Michael and Bill through this next exciting phase, and pursue the Company’s mission to reduce cancer deaths and suffering by commercializing our novel early-cancer detection approach from a routine blood draw.”
Cancer is a leading cause of death worldwide, accounting for an estimated 9.6 million deaths. When cancer is detected early, it is generally still curable, and both cancer management and societal costs are drastically lowered. The World Health Organization (WHO) estimates that worldwide, the annual economic cost of cancer in 2010 was approximately $1.2 trillion and increasing. Acuamark’s novel assays are designed to provide best-in-class, cost-effective blood-based screening for all major early-cancers. AcuamarkDx estimates that broadly-accessible, affordable and reliable early cancer screening can increase screening compliance and reduce cancer deaths by up to 55%.
About Acuamark Diagnostics Inc.
Acuamark Diagnostics is a biotechnology company focused on developing novel and unique screening tests for blood-based early-detection of cancer. Acuamark Diagnostics' technology allows for highly reliable and cost-effective screening of blood to detect cancer markers at the early cancer stages when cure rates are high. Backed by a highly experienced industry team and world-renowned scientific team, it is Acuamark Diagnostics’ mission to reduce cancer deaths and suffering by intercepting cancer at the earliest stages through commercialization of a reliable, cost-effective and convenient high-throughput approach from a simple blood draw.
AcuamarkDx’s Board of Directors is comprised of Mr. William Gedale (Executive Chairman), Mr. Michael Gargano, Mr. Howard Johnson, Mr. Gregory Murdock, Mr. Joseph Smith, Dr. Vanja Vuletic and Dr. Bernard Peperstraete (President, CEO).
For more information, please visit www.acuamarkdx.com, or contact us at